Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Dermatology

Thriving with PV: Long-Term Monitoring and Daily Life

At a Glance

Long-term Pemphigus Vulgaris (PV) management aims for clinical remission. Daily care involves pain control, gentle skin dressings, and infection precautions due to immunosuppressive treatments. Doctors monitor progress through Dsg blood tests and may recommend future Rituximab boosters.

Transitioning from the crisis of a new diagnosis to long-term survivorship is a major milestone. While Pemphigus Vulgaris (PV) is a chronic condition, the goal of modern care is to move you into a state of “clinical remission off-therapy,” where you can live your life without active blisters or the need for daily heavy medications [1][2].

Surviving the Day-to-Day: Managing Pain and Wounds

Before remission is fully achieved, managing the daily reality of PV requires practical strategies.

Managing Excruciating Mouth Pain

Mouth erosions can make eating and drinking nearly impossible, putting you at risk for dehydration and malnutrition [3].

  • Pain Relief: Ask your oral medicine specialist or dermatologist for prescription numbing agents, such as viscous lidocaine, to use right before meals [4].
  • The Soft Diet: Avoid sharp, rough, hot, or highly acidic foods (like crusty bread, tomatoes, or citrus) that physically tear the fragile lining of the mouth [3].
  • Temperature Control: Eat foods that are lukewarm or cool. Smoothies, blended soups, and soft pastas are often well-tolerated.

Gentle Skin Care

  • Treat open erosions on your skin like a second-degree burn. Use gentle, non-adherent dressings [5].
  • Avoid Adhesives: Never use standard Band-Aids or medical tape directly on fragile skin. Removing them can cause the top layer of skin to peel off (a positive Nikolsky sign) [6].

Daily Infection Precautions

Because you are likely on high-dose steroids and/or Rituximab, your immune system is severely compromised [7]. You must be proactive about infection prevention:

  • Wear a high-quality (N95 or KN95) mask in crowded indoor spaces [8].
  • Practice rigorous handwashing and carry hand sanitizer.
  • Avoid contact with individuals who are sick, even if it’s “just a cold.”

Monitoring Your Progress

Once your initial symptoms are under control, your care team will track your health through a combination of physical exams and blood work.

Titer Monitoring and “Titer Anxiety”

Your doctor will periodically order an ELISA blood test to check your anti-desmoglein (Dsg) 1 and 3 titers [9].

  • The Trend Matters: Generally, as your disease gets quieter, these numbers should go down [10].
  • The “Discordance” Factor: It is important to know that titers are not perfect. Some patients have high titers but perfectly clear skin, while others may flare even with low numbers [11].
  • Managing Anxiety: Many patients experience intense “titer anxiety” while waiting for results. Remember that your doctor treats you, not just the number on the page; clinical symptoms (new blisters) are often given more weight than the lab result alone [11][12].

The Relapse and Booster Timeline

Because the immune system has a long memory, PV can sometimes return after the initial treatment.

  • Typical Timeline: If a relapse occurs, it often happens around 12–15 months after your first Rituximab infusion, though this varies greatly by individual [13][14].
  • Booster Strategies: Some doctors use a “fixed-interval” approach (a booster every 6 months), while others use an “on-demand” approach (a booster only if symptoms or titers start to rise) [15][16].

The Psychological Journey

The impact of PV is not just skin deep. The chronic nature of the disease, the pain, and the visible nature of the lesions can lead to social isolation and distress [17][18]. Don’t hesitate to seek out specialized support groups, such as those run by the International Pemphigus & Pemphigoid Foundation (IPPF), as connecting with others who understand the unique challenges of PV can significantly reduce the emotional burden of the disease [19][20].

🛡️You are a survivor, and with modern care, your future is bright. [21]

Common questions in this guide

How can I manage excruciating mouth pain from Pemphigus Vulgaris?
To manage mouth pain from PV erosions, stick to a soft diet of lukewarm or cool foods and avoid sharp, acidic, or hot foods. Your doctor can also prescribe numbing agents like viscous lidocaine to use right before meals.
What does an ELISA blood test measure for Pemphigus Vulgaris?
An ELISA blood test checks your anti-desmoglein (Dsg) 1 and 3 titers. Monitoring these antibody levels helps your doctor track disease activity over time, though your physical symptoms are often considered more important than the exact numbers.
Will I need a Rituximab booster for Pemphigus Vulgaris?
Many patients require Rituximab boosters because PV can relapse over time. Some doctors prescribe boosters on a fixed schedule, such as every 6 months, while others wait to see if symptoms or antibody titers begin to rise before giving a booster.
How should I care for skin erosions caused by PV?
Treat open skin erosions gently, similar to a second-degree burn, using non-adherent dressings. You should avoid using standard medical tape or adhesive bandages directly on your skin, as removing them can cause the fragile top layer to peel off.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the current trend of my anti-Dsg1 and anti-Dsg3 titers, and how does it correlate with what you see on my skin/mucosa?
  2. 2.If my titers rise but I have no new blisters, will we increase my medication or take a 'wait and see' approach?
  3. 3.Am I on a fixed-interval schedule for Rituximab boosters (e.g., every 6 months) or an 'on-demand' schedule based on my symptoms?
  4. 4.What are the specific signs of a 'mini-flare' that should prompt me to call you before my next scheduled appointment?
  5. 5.Can you recommend a clinical dietitian or nutritionist who understands the limitations of eating with severe mucosal PV?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.

    Werth VP, Joly P, Mimouni D, et al.

    The New England journal of medicine 2021; (384(24)):2295-2305 doi:10.1056/NEJMoa2028564.

    PMID: 34097368
  2. 2

    Pemphigus Vulgaris: Present and Future Therapeutic Strategies.

    Didona D, Paolino G, Di Zenzo G, et al.

    Dermatology practical & conceptual 2022; (12(1)):e2022037 doi:10.5826/dpc.1201a37.

    PMID: 35223181
  3. 3

    Oral Lesions in Autoimmune Bullous Diseases: An Overview of Clinical Characteristics and Diagnostic Algorithm.

    Rashid H, Lamberts A, Diercks GFH, et al.

    American journal of clinical dermatology 2019; (20(6)):847-861 doi:10.1007/s40257-019-00461-7.

    PMID: 31313078
  4. 4

    An Oral Disease Severity Score validated for use in oral pemphigus vulgaris.

    Ormond M, McParland H, Donaldson ANA, et al.

    The British journal of dermatology 2018; (179(4)):872-881 doi:10.1111/bjd.16265.

    PMID: 29297927
  5. 5

    Bullous pemphigoid and pemphigus vulgaris.

    Kayani M, Aslam AM

    BMJ (Clinical research ed.) 2017; (357()):j2169 doi:10.1136/bmj.j2169.

    PMID: 28596152
  6. 6

    Current status and prospects for the diagnosis of pemphigus vulgaris.

    Nili A, Salehi Farid A, Asgari M, et al.

    Expert review of clinical immunology 2021; (17(8)):819-834 doi:10.1080/1744666X.2021.1945925.

    PMID: 34162306
  7. 7

    A Case Report of Pemphigus Vulgaris Initially Misdiagnosed as Tinea Capitis: Infectious Consequences of Diagnostic Delay in a Patient Treated With Rituximab.

    González-Rodríguez JC, Cristofori M, Antunez Oliva JA, Cortés-Marín EE

    Cureus 2025; (17(7)):e87662 doi:10.7759/cureus.87662.

    PMID: 40673286
  8. 8

    Rituximab as a maintenance treatment in patients with pemphigus vulgaris: When is the right time for discontinuation?

    Aryanian Z, Balighi K, Emadi SN, Hatami P

    Journal of cosmetic dermatology 2024; (23(2)):406-408 doi:10.1111/jocd.16030.

    PMID: 37916650
  9. 9

    Serologic Biomarkers in Pemphigus Monitoring: C-reactive Protein, Macrophage Migration Inhibitory Factor, and Prolactin Levels Versus Autoantibody Assays.

    Mortazavi H, Saeidi V, Balighi K, et al.

    Iranian journal of allergy, asthma, and immunology 2023; (22(3)):312-318 doi:10.18502/ijaai.v22i3.13059.

    PMID: 37524667
  10. 10

    Pemphigus vulgaris disease activity: The role of antibodies to desmogleins and their isotype.

    Yeoh SC, Byth-Wilson K, Murrell DF, et al.

    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2019; (48(7)):619-625 doi:10.1111/jop.12913.

    PMID: 31192484
  11. 11

    [Clinical Analysis of Eight Cases of Pemphigus with High Titers of Anti-desmoglein Antibodies in Remission].

    Jin XX, Li SZ, Zuo YG, Jin HZ

    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 2021; (43(2)):166-172 doi:10.3881/j.issn.1000-503X.13452.

    PMID: 33966693
  12. 12

    Evaluation of the pathogenicity of anti-desmoglein antibodies of pemphigus vulgaris patients using human organ culture assay.

    Saleh AM, El-Samanoudy SI, Rashed LA, Saleh MA

    Archives of dermatological research 2020; (312(4)):289-294 doi:10.1007/s00403-019-01988-9.

    PMID: 31587106
  13. 13

    Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris.

    Raviv T, Pevzner K, Barzilai A, et al.

    Acta dermato-venereologica 2025; (105()):adv27140 doi:10.2340/actadv.v105.27140.

    PMID: 39749385
  14. 14

    Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris.

    Tovanabutra N, Bax CE, Feng R, et al.

    The Journal of investigative dermatology 2022; (142(4)):1058-1064.e7 doi:10.1016/j.jid.2021.09.013.

    PMID: 34710389
  15. 15

    Clinical practice guidelines for rituximab treatment in children with steroid-sensitive nephrotic syndrome.

    Shen Q, Xia ZK, Liu JL, et al.

    World journal of pediatrics : WJP 2025; (21(8)):775-791 doi:10.1007/s12519-025-00957-9.

    PMID: 40802032
  16. 16

    Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

    Charles P, Terrier B, Perrodeau É, et al.

    Annals of the rheumatic diseases 2018; (77(8)):1143-1149 doi:10.1136/annrheumdis-2017-212878.

    PMID: 29695500
  17. 17

    Quality of life remains poor for patients with pemphigus vulgaris despite targeted therapies.

    Schultz B, Latour E, Fett N

    The British journal of dermatology 2019; (181(5)):1101-1103 doi:10.1111/bjd.18167.

    PMID: 31127954
  18. 18

    Evaluation of the Quality of Life and the Demographic and Clinical Characteristics of Patients With Pemphigus With Oral Mucosal İnvolvement: A Multicenter Observational Study.

    Polat AK, Mülayim MK, Gür TF, et al.

    Dermatology practical & conceptual 2024; (14(2)) doi:10.5826/dpc.1402a99.

    PMID: 38810063
  19. 19

    The health-related quality of life and psychological profile in patients with oropharyngeal Pemphigus Vulgaris in complete clinical remission: A case-control study.

    Calabria E, Adamo D, Leuci S, et al.

    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2021; (50(5)):510-519 doi:10.1111/jop.13150.

    PMID: 33314320
  20. 20

    Burden of pemphigus vulgaris with a particular focus on women: A review.

    Kianfar N, Dasdar S, Mahmoudi H, Daneshpazhooh M

    International journal of women's dermatology 2022; (8(3)):e056 doi:10.1097/JW9.0000000000000056.

    PMID: 36204194
  21. 21

    Biologics in autoimmune bullous diseases: Current scenario.

    Bishnoi A, De D, Handa S, Mahajan R

    Indian journal of dermatology, venereology and leprology 2021; (87(5)):611-620.

    PMID: 34245525

This page provides educational information about managing day-to-day life with Pemphigus Vulgaris. It is not a substitute for professional medical advice from your dermatologist or oral medicine specialist.

Get notified when new evidence is published on Pemphigus vulgaris.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.